Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV co-infected patients.

Trial Profile

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV co-infected patients.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 May 2018

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EARLY HEP-C
  • Most Recent Events

    • 27 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.
    • 27 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 13 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top